DrugDashboards

Sirolimus

Sirolimus · SIROLIMUS 1 mg/mL · Solution · Oral · VistaPharm, LLC

NDC 66689-0347-02 · 1 CARTON in 1 KIT / 1 BOTTLE in 1 CARTON / 60 mL in 1 BOTTLE · ANDA · View full market →

The short version

9 companies supply this market — a reasonable cushion if one runs into trouble. The price has held steady around $4.56 per mL over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$4.56per MLinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$5.75per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$14.50per unitnegotiated price across 5,496 plans — before rebates · Apr 1, 2026
  • Federal contracts pay (FSS)$596.40per package of 60MLGolden State Medical Supply, Inc. · Jun 16, 2023
  • Medicaid generic ceiling (FUL)$4.75per MLweighted avg manufacturer price $2.7154 · Aug 1, 2026104% of what pharmacies pay — higher than 62% of drugs with this benchmark

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$14.50per unit
middle half $9.77$15.75 · 5,496 plans · Apr 1, 2026
Est. net of rebates
≈ $14.50
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
100%of plans cover it
tier 4 · prior auth 100% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$10.00$20.00Feb 2021Sep 2026$4.56
32 price points · per ML · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

WAC per package, as filed
$601.75
Reported to Texas DSHS · 2026 annual filing · PAI Holdings LLC dba Pharmaceutical Associates, Inc. / PAI Pharma

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$241,685
484 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

0Low risk

Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for sirolimus (other) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
ANDA211040
TE code
AA
Approval date
Jan 28, 2019
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Sirolimus (Solution)

LabelerStrengthFirst seenLast seen
Amneal Pharmaceuticals NY LLCSIROLIMUS 1 mg/mLJul 15, 2026Sep 2, 2026
Apotex CorpSIROLIMUS 1 mg/mLJul 15, 2026Sep 2, 2026
Bryant Ranch PrepackSIROLIMUS 1 mg/mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.SIROLIMUS 1 mg/mLJul 15, 2026Sep 2, 2026
Mylan Pharmaceuticals Inc.SIROLIMUS 1 mg/mLJul 15, 2026Sep 2, 2026
Northstar Rx LLCSIROLIMUS 1 mg/mLJul 15, 2026Sep 2, 2026
Novadoz Pharmaceuticals LLCSIROLIMUS 1 mg/mLJul 15, 2026Sep 2, 2026
Rising Pharma Holdings, Inc.SIROLIMUS 1 mg/mLJul 15, 2026Sep 2, 2026
VistaPharm, LLCSIROLIMUS 1 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Sirolimus — NDC 66689-0347-02," retrieved September 3, 2026, https://drugdashboards.com/drug/66689034702.

Free to cite with attribution — see how the data is put together.